Ectopic expression of Fas Ligand on cardiomyocytes renders cardiac allografts resistant to CD4+ T-cell mediated rejection

被引:7
|
作者
Plenter, Robert J. [1 ,2 ]
Grazia, Todd J. [1 ,2 ]
Nelson, David P. [3 ]
Zamora, Martin R. [1 ,2 ]
Gill, Ronald G. [1 ]
Pietra, Biagio A. [1 ,4 ]
机构
[1] Univ Colorado Denver, Colorado Ctr Transplantat Care,Res & Educ, Dept Surg, Aurora, CO 80045 USA
[2] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO 80045 USA
[3] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH 45229 USA
[4] Colorado Childrens Hosp, Dept Pediat, Aurora, CO 80045 USA
关键词
Rejection; Fas Ligand; Transplantation; ANTI-CD4; MONOCLONAL-ANTIBODY; ACTIVATION-INDUCED CELL; IMMUNE PRIVILEGE; TOLERANCE; DONOR; INDUCTION; TRANSPLANTATION; SURVIVAL; ISLETS; HEART;
D O I
10.1016/j.cellimm.2014.11.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Fas Ligand limits inflammatory injury and permits allograft survival by inducing apoptosis of Fas-bearing lymphocytes. Previous studies have shown that the CD4(+) T-cell is both sufficient and required for murine cardiac allograft rejection. Here, utilizing a transgenic mouse that over-expresses Fas Ligand specifically on cardiomyocytes as heart donors, we sought to determine if Fas Ligand on graft parenchymal cells could resist CD4(+) T-cell mediated rejection. When transplanted into fully immunocompetent BALB/c recipients Fas Ligand transgenic hearts were acutely rejected. However, when transplanted into CD4(+) T-cell reconstituted BALB/c-rag(-/-) recipients, Fas Ligand hearts demonstrated long-term survival. These results indicate that Fas Ligand over-expression on cardiomyocytes can indeed resist CD4(+) T-cell mediated cardiac rejection and suggests contact dependence between as Ligand expressing graft parenchymal cells and the effector CD4(+) T-cells. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:30 / 33
页数:4
相关论文
共 50 条
  • [31] Boosting CD4+ T-cell restoration
    不详
    IMMUNOTHERAPY, 2009, 1 (03) : 335 - 335
  • [32] Donor IFN-γ receptors are critical for acute CD4+ T cell-mediated cardiac allograft rejection
    Wiseman, AC
    Pietra, BA
    Kelly, BP
    Rayat, GR
    Rizeq, M
    Gill, RG
    JOURNAL OF IMMUNOLOGY, 2001, 167 (09): : 5457 - 5463
  • [33] MURINE CD4+ T-CELL SUBSETS
    HAYAKAWA, K
    HARDY, RR
    IMMUNOLOGICAL REVIEWS, 1991, 123 : 145 - 168
  • [34] CD4+ T-cell subsets in autoimmunity
    O'Garra, A
    Steinman, L
    Gijbels, K
    CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (06) : 872 - 883
  • [35] Idiopathic CD4+ T-cell lymphocytopenia
    Aparna Mukherjee
    Rakesh Lodha
    S. K. Kabra
    The Indian Journal of Pediatrics, 2009, 76 : 430 - 432
  • [36] CD4+ T-cell subsets in transplantation
    Liu, Zhongmin
    Fan, Huimin
    Jiang, Shuiping
    IMMUNOLOGICAL REVIEWS, 2013, 252 : 183 - 191
  • [37] Differential control of autoantibodies and lymphoproliferation by Fas ligand expression on CD4+ and CD8+ T cells in vivo
    Maldonado, MA
    MacDonald, GC
    Kakkanaiah, VN
    Fecho, K
    Dransfield, M
    Sekiguchi, D
    Cohen, PL
    Eisenberg, RA
    JOURNAL OF IMMUNOLOGY, 1999, 163 (06): : 3138 - 3142
  • [38] FAS ANTIGEN IS THE MAJOR TARGET MOLECULE FOR CD4+ T-CELL-MEDIATED CYTOTOXICITY
    STALDER, T
    HAHN, SH
    ERB, P
    JOURNAL OF IMMUNOLOGY, 1994, 152 (03): : 1127 - 1133
  • [39] Rejection of cardiac xenografts by CD4+ and CD8+ T cells
    Cao, R
    Chen, D
    Guo, H
    Chen, G
    Wang, XM
    Shen, SQ
    Chen, S
    XENOTRANSPLANTATION, 2003, 10 (05) : 531 - 531
  • [40] Rejection of cardiac xenografts by CD4+ or CD8+ T cells
    Lin, Y
    Soares, MP
    Sato, K
    Takigami, K
    Csizmadia, E
    Anrather, J
    Bach, FH
    JOURNAL OF IMMUNOLOGY, 1999, 162 (02): : 1206 - 1214